| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 05/02/2001 | EP1095060A1 Galectin 11 |
| 05/02/2001 | EP1095059A1 Chemotaxis inhibiting protein of staphylococcus (chips) and its use |
| 05/02/2001 | EP1095057A1 Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof |
| 05/02/2001 | EP1095039A2 New pharmaceutically active compounds |
| 05/02/2001 | EP1095036A1 Cinnamic acid derivatives as cell adhesion molecules |
| 05/02/2001 | EP1095021A1 Quinoline derivatives |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095018A1 Aminoiminoquinone and aminoquinone alkaloid compounds as caspase inhibitors |
| 05/02/2001 | EP1095003A1 Cytokine production and tyrosine kinase inhibitors |
| 05/02/2001 | EP1094840A1 Use of texaphyrins in macrophage-mediated disease |
| 05/02/2001 | EP1094833A2 Oxidized thymosin beta 4 |
| 05/02/2001 | EP1094832A1 Therapeutic use of uncoupling protein-hhfcw60 |
| 05/02/2001 | EP1094828A1 Use of neglected target tissue antigens in modulation of immune responses |
| 05/02/2001 | EP1094818A1 Use of tricyclic antidepressants for local analgesia |
| 05/02/2001 | EP1094815A1 Farnesyl protein transferase inhibitors for treating arthropathies |
| 05/02/2001 | EP1094802A1 Pharmaceutical composition for injection based on paracetamol |
| 05/02/2001 | EP1094796A1 Topical plaster with non-steroidal antirheumatic agents with an acid group |
| 05/02/2001 | EP0984959A4 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| 05/02/2001 | EP0983257A4 Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| 05/02/2001 | EP0973392A4 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 05/02/2001 | EP0966427B1 Preparation of acid amides and metallisation of compounds |
| 05/02/2001 | EP0769947B1 Indolinone compounds for the treatment of disease |
| 05/02/2001 | CN1293674A Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient |
| 05/02/2001 | CN1293663A 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamix acids as matrix metal-protease |
| 05/02/2001 | CN1293662A Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| 05/01/2001 | US6225494 Trisubstituted phenyl derivatives having retinoid agonist or inverse agonist type biological activity |
| 05/01/2001 | US6225354 Subjecting unsaponified beeswax to liquid extraction with liquid organic extractant in which primary aliphatic alcohols are soluble; recovering alcohol mixture and isolating alcohols |
| 05/01/2001 | US6225351 For therapy of asthma, arthritis, and sepsis bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis, sepsis, septic shock, cachexia, acquire immuno deficiency syndrome (aids) |
| 05/01/2001 | US6225339 Terpenoid lactone compounds and their production process |
| 05/01/2001 | US6225335 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease |
| 05/01/2001 | US6225328 Adamantyl-substituted retinoids and pharmaceutical/cosmetic compositions comprised thereof |
| 05/01/2001 | US6225320 Treatment of pain, inflammation, migraine, emesis and posttherpetic neuralgia |
| 05/01/2001 | US6225316 3-phenyl-pyridine-derivatives |
| 05/01/2001 | US6225302 Amidino protease inhibitors |
| 05/01/2001 | US6225300 TNF receptor and steroid hormone in a combined therapy |
| 05/01/2001 | US6225284 Somatostatin peptides |
| 05/01/2001 | US6225117 Antibodies against human IL-12 |
| 05/01/2001 | US6225087 Polynucleotide which codes for a polypeptide of defined amino acid sequence; drug screening of bactericides against streptococcus; otitis media; conjunctivitis; pneumonia; meningitis; sinusitis; pleural empyema; endocarditis |
| 05/01/2001 | US6224875 Tanacetum parthenium extract and method of obtaining same |
| 05/01/2001 | CA2186919C Therapeutic anti-inflammatory and analgesic pharmaceutical composition containing nimesulide 4-nitro, 2 phenoxyphenyl methane sulphonamide for use transdermally and a process for the manufacture thereof |
| 05/01/2001 | CA2121473C Methods and compositions for treating allergic reactions |
| 05/01/2001 | CA2046303C Il-1 biological activity inhibitors |
| 04/26/2001 | WO2001029564A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies |
| 04/26/2001 | WO2001029178A2 Epo primary response gene 1, eprg1 |
| 04/26/2001 | WO2001029070A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 04/26/2001 | WO2001029049A2 Imidazole derivatives as phosphodiesterase vii inhibitors |
| 04/26/2001 | WO2001029042A1 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 04/26/2001 | WO2001029041A1 Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 04/26/2001 | WO2001029038A1 Tricyclic fused-imidazole derivatives |
| 04/26/2001 | WO2001029028A1 9- (piperazinylalkyl) carbazoles as bax-modulators |
| 04/26/2001 | WO2001029026A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 04/26/2001 | WO2001029025A2 Tyrosine kinase inhibitors |
| 04/26/2001 | WO2001029012A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029009A1 4,5-disubstituted-2-aminopyrimidines |
| 04/26/2001 | WO2001029007A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 04/26/2001 | WO2001029000A2 Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| 04/26/2001 | WO2001028993A2 Tyrosine kinase inhibitors |
| 04/26/2001 | WO2001028987A1 Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| 04/26/2001 | WO2001028616A1 Medicament pack |
| 04/26/2001 | WO2001028591A2 Injection vehicle for polymer-based formulations |
| 04/26/2001 | WO2001028580A2 Modulation of angiogenesis |
| 04/26/2001 | WO2001028557A1 Cannabimimetic indole derivatives |
| 04/26/2001 | WO2001028523A1 Powder pharmaceutical formulations |
| 04/26/2001 | WO2001028515A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 04/26/2001 | WO2001028497A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 04/26/2001 | WO2001003645A3 Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| 04/26/2001 | WO2000077040A3 Human intracellular signaling molecules |
| 04/26/2001 | WO2000074703A3 Therapeutic agent comprising a botulinum neurotoxin |
| 04/26/2001 | WO2000064486A3 Enzymatically activated polymeric drug conjugates |
| 04/26/2001 | WO2000061609B1 Prodrugs of thrombin inhibitors |
| 04/26/2001 | WO2000056889A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/26/2001 | WO2000055139A3 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 04/26/2001 | WO2000055125A3 N-cyanomethyl amides as protease inhibitors |
| 04/26/2001 | US20010000513 Treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation |
| 04/26/2001 | DE19950647A1 Benzopyranoimidazolone and benzothiopyranoimidazolone derivatives as phosphodiesterase-VII inhibitors useful for treatment of e.g. asthma, psoriasis, osteoporosis, cachexia, sepsis, tumors and AIDS |
| 04/26/2001 | CA2389317A1 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 04/26/2001 | CA2388503A1 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 04/26/2001 | CA2387892A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 04/26/2001 | CA2387840A1 Tyrosine kinase inhibitors |
| 04/26/2001 | CA2387138A1 Cannabimimetic indole derivatives |
| 04/26/2001 | CA2387034A1 4,5-disubstituted-2-aminopyrimidines |
| 04/26/2001 | CA2386922A1 Novel polypeptides and polynucleotides encoding same |
| 04/26/2001 | CA2386422A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 04/26/2001 | CA2386049A1 Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| 04/26/2001 | CA2384537A1 Modulation of angiogenesis |
| 04/26/2001 | CA2384264A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies |
| 04/26/2001 | CA2384240A1 Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| 04/26/2001 | CA2382978A1 Powder pharmaceutical formulations |
| 04/25/2001 | EP1094109A2 Human G protein-coupled receptor, PFI-010 |
| 04/25/2001 | EP1094075A1 Human G-protein coupled receptor |
| 04/25/2001 | EP1094063A1 9-(Piperazinylalkyl)carbazoles as Bax-modulators |
| 04/25/2001 | EP1093814A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 04/25/2001 | EP1093521A2 Human transferases |
| 04/25/2001 | EP1093457A1 Cytokine receptor common gamma chain like |
| 04/25/2001 | EP1093379A2 Use of inhibitors of protein kinase c epsilon to treat pain |
| 04/25/2001 | EP1093374A1 Hypo-osmotic saline solutions, method for preparing same and medicines based on said solutions |
| 04/25/2001 | EP1093371A1 Use of fk506 and related macrolides in the manufacture of a medicament for treatment or prevention of pain |
| 04/25/2001 | EP1093367A1 Protease inhibitors |
| 04/25/2001 | EP1007068A4 Process for preparing synthetic soil-extract materials and medicaments based thereon |
| 04/25/2001 | EP0701568B1 New peptide derivatives |